National Cancer Centre Singapore (NCCS) shared a post on LinkedIn:
“One of the most aggressive breast cancer subtypes, triple-negative breast cancer (TNBC) makes up 10-20% of breast cancers in Singapore. Often affecting young women under the age of 40, TNBC is associated with early recurrence, high chance of spread and shorter survival.
The good news? There may be a novel treatment option on the horizon soon for these patients.
Prof Rebecca Dent, Deputy CEO (Clinical) and Senior Consultant, Div of Medical Oncology, NCCS recently led a study showing that the antibody-drug conjugate datopotamab deruxtecan (Dato-DxD) nearly doubled the time that inoperable, untreated TNBC patients lived without the disease progressing.
The trial was carried out across the globe, in countries that included the United States, Canada, Europe, China, Korea, Japan and Singapore.
Read more about the study in The Straits Times coverage.”
Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02
